» Articles » PMID: 7741164

Endemic Kala-azar in Eastern Sudan: Post-kala-azar Dermal Leishmaniasis

Overview
Specialty Tropical Medicine
Date 1995 Apr 1
PMID 7741164
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

In a longitudinal study between 1991 and 1993 in an endemic area in eastern Sudan, 85 cases of kala-azar (visceral leishmaniasis) were diagnosed, of whom 48 (56%) developed post-kala-azar dermal leishmaniasis (PKDL). Another four cases of PKDL had no clinical history of kala-azar. In children, PKDL was more frequent in the very young; seven of nine kala-azar cases (78%) in the group 0-1 years of age and 13 of 16 (81%) in the group 2-3 years of age developed PKDL. On the average, PKDL occurred 56 days (mean; range 0-180) after the end of treatment of kala-azar. To assess the severity of PKDL, a classification was developed using three grades of severity based on differences in density and distribution of lesions. In young children, PKDL was more severe. Incomplete treatment of kala-azar may be important in the pathogenesis of PKDL. Thirty-one patients were followed-up for at least six months; of these, 20 were not treated (17 healed, two improved, and in one, the condition was unchanged), three healed after incomplete treatment with sodium stibogluconate, and eight were cured after treatment but two required two courses. Considerable morbidity was caused by PKDL and should be taken into consideration in the management and follow-up of kala-azar patients. The high incidence of PKDL may have important implications in transmission.

Citing Articles

A randomized, double-blind phase 2b trial to evaluate efficacy of ChAd63-KH for treatment of post kala-azar dermal leishmaniasis.

Younis B, Wiggins R, Khalil E, Osman M, Santoro F, Sonnati C Mol Ther Methods Clin Dev. 2024; 32(3):101310.

PMID: 39253357 PMC: 11381778. DOI: 10.1016/j.omtm.2024.101310.


Visceral leishmaniasis follow-up and treatment outcomes in Tiaty East and West sub-counties, Kenya: Cure, relapse, and Post Kala-azar Dermal Leishmaniasis.

Kennedy G, OBrien K, Nyakundi H, Kitondo M, Biwott W, Wamai R PLoS One. 2024; 19(6):e0306067.

PMID: 38917127 PMC: 11198830. DOI: 10.1371/journal.pone.0306067.


Post-kala-azar dermal leishmaniasis (PKDL) drug efficacy study landscape: A systematic scoping review of clinical trials and observational studies to assess the feasibility of establishing an individual participant-level data (IPD) platform.

Singh-Phulgenda S, Kumar R, Dahal P, Munir A, Rashan S, Chhajed R PLoS Negl Trop Dis. 2024; 18(4):e0011635.

PMID: 38626228 PMC: 11051605. DOI: 10.1371/journal.pntd.0011635.


Case Report: An Atypical Case of Post-Kala-Azar Dermal Leishmaniasis with Ulcers and Verrucous Lesions: Clinical and Therapeutic Implications.

Mathachan S, Khurana A, Bansal A, Singhai M, Kumari R, Sardana K Am J Trop Med Hyg. 2023; 110(1):40-43.

PMID: 38011733 PMC: 10793023. DOI: 10.4269/ajtmh.23-0448.


Evaluation of molecular assays to detect Leishmania donovani in Phlebotomus argentipes fed on post-kala-azar dermal leishmaniasis patients.

Khan M, Faisal K, Chowdhury R, Nath R, Ghosh P, Ghosh D Parasit Vectors. 2021; 14(1):465.

PMID: 34503557 PMC: 8428120. DOI: 10.1186/s13071-021-04961-6.